Alcon AG stock hits 52-week low at $74.83

Alcon AG stock has reached a 52-week low, hitting $74.83, marking a significant milestone for the $37 billion market cap healthcare equipment company. According to InvestingPro analysis, the stock appears slightly undervalued at current levels. Over the past year, the company’s stock has experienced a notable decline, with a 1-year change of -24.09%. Despite generating over $10 billion in revenue and maintaining a GOOD financial health score, this downturn reflects various market dynamics and challenges. With a beta of 0.69, the stock historically shows lower volatility than the broader market. InvestingPro subscribers can access 8 additional key insights about Alcon’s market position and financial outlook. The new 52-week low underscores current market pressures, though analyst targets suggest potential upside, with price targets ranging from $77.53 to $123. For comprehensive analysis, including detailed valuation metrics and growth prospects, investors can access Alcon’s full Pro Research Report on InvestingPro.

In other recent news, Alcon Inc. has faced several analyst revisions following its second-quarter performance and guidance adjustments. Bernstein SocGen Group lowered its price target for Alcon to $104.65, citing a disappointing second quarter and a guidance downgrade. Similarly, BofA Securities reduced its price target to $100, maintaining a Buy rating despite a recent profit warning from Alcon concerning soft surgical procedure volumes and rising competitive pressures. JPMorgan also downgraded Alcon from Overweight to Neutral, reducing its price target to CHF62.80 due to another soft quarter and guidance cut, which may impact fiscal year 2026 growth expectations. Deutsche Bank adjusted its price target on Alcon to CHF69.00, maintaining a Hold rating, amid concerns about the company’s limited visibility into market conditions. Meanwhile, Broadwood Partners, the largest shareholder of STAAR Surgical Company, expressed opposition to Alcon’s proposed acquisition of STAAR Surgical at $28 per share. Broadwood criticized the timing, process, and price of the transaction, suggesting that STAAR’s recent challenges are temporary and the company is poised for growth and profitability. These developments highlight the challenges Alcon faces in navigating market conditions and strategic decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.